Postoperative Serum Albumin is a Potential Prognostic Factor for Older Patients with Gastric Cancer by Saito, Hiroaki et al.
72
Yonago Acta Medica 2018;61:072–078   Original Article
Corresponding author: Hiroaki Saito, MD, PhD
sai10@med.tottori-u.ac.jp
Received 2017 September 13
Accepted 2018 February 5 
Abbreviations: Alb, albumin; ASA, American Society of Anaesthe-
siologists; AUC, area under the curve; CONUT, controlling nutri-
tion status; DSS, disease-specific survival; GC, gastric cancer; OS, 
overall survival, PNI, prognostic nutritional index; ROC, receiver 
operating characteristic
Postoperative Serum Albumin is a Potential Prognostic Factor for Older Patients 
with Gastric Cancer
Hiroaki Saito, Yusuke Kono, Yuki Murakami, Yuji Shishido, Hirohiko Kuroda, Tomoyuki Matsunaga, Yoji 
Fukumoto, Tomohiro Osaki, Keigo Ashida, and Yoshiyuki Fujiwara
Division of Surgical Oncology, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8504, 
Japan
ABSTRACT
Background    The incidence of gastric cancer (GC) 
among older adults is increasing. Therefore, determining 
postoperative age-associated prognostic factors is clini-
cally important. This study retrospectively investigated 
the prognostic significance of serum albumin level in 
older GC patients.
Methods    We enrolled 135 patients aged ≥ 75 years, 
who underwent gastrectomies with histopathological di-
agnoses of gastric adenocarcinoma.
Results    Preoperative albumin (pre-Alb) levels in 
patients with advanced GC and stage III/IV GC were 
significantly lower than those in patients with early GC 
(P = 0.0032) and stage I/II GC (P = 0.006), respective-
ly. Postoperative albumin (post-Alb) levels (measured 
1 month after surgery) in male patients and in patients 
with advanced GC were significantly lower than those in 
female patients (P = 0.024) and those with early GC (P = 
0.044), respectively. Post-Alb levels of patients who died 
of other diseases were significantly lower than those who 
were still living (P = 0.0004). Prognosis of patients with 
high post-Alb levels (≥ 4g/dL) was significantly better 
than that of patients with low post-Alb levels (< 4g/dL; P 
= 0.045); and in multivariate analysis, post-Alb level was 
an independent prognostic indicator.
Conclusion    Post-Alb level is a useful predictive factor 
for the prognosis of older GC patients. Postoperative 
nutritional support might help improve the prognosis of 
older GC patients.
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Gastric cancer (GC) is one of the most common cancers 
worldwide. In fact, 989,600 new GC cases and 738,000 
GC deaths were estimated to have occurred in 2008, 
thus accounting for 8% of the total cancer cases and 10% 
of the total cancer deaths.1 The incidence of GC among 
the older population is increasing in Japan owing to the 
extended life span of the current population.2 Therefore, 
determining postoperative, age-associated prognostic 
factors are clinically important. 
 Accumulating evidence indicate that markers that 
reflect nutrition are associated with prognosis of cancer 
patients.3–9 Although various methods for evaluating nu-
tritional status are available, serum albumin level is still 
the conventional and standard indicator in routine clini-
cal settings. Serum albumin is produced in the liver and 
is the most abundant blood plasma protein. Low serum 
albumin levels reportedly indicate an increased risk of 
mortality and morbidity among hospitalized patients.10–13 
Furthermore, preoperative serum albumin (pre-Alb) 
level has been shown to be a prognostic indicator in 
various cancers, including GC.14 However, these studies 
focused on the correlation between prognosis and pre-
Alb level. As gastrectomy, which is a common treatment 
for GC, decreases stomach volume, some patients’ post-
operative nutritional status worsens in comparison with 
their preoperative nutritional status. Therefore, poor 
postoperative nutritional status might be related to poor 
prognosis in patients with GC. However, little research 
has been undertaken to examine the correlation between 
postoperative nutritional status and the prognosis of GC 
patients thus far. 
 Compared with younger people, the metabolic rate 
of older patients is altered; the cells undergo deformation 
and functional impairment, and major organs show re-
duced function or cell loss. In addition, with increasing 
age, tissue and cell regeneration is reduced, leading to 
slower recovery of bodily functions. Because adequate 
nutrition is vitally important for patients who undergo 
surgery, older patients may be more sensitive to malnu-
trition than younger patients. In the current study, we 
therefore examined the prognostic significance of not 
only pre-Alb level but also postoperative serum albumin 
(post-Alb) level in older GC patients.
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MATERIALS AND METHODS
Patients 
This study was based on a retrospective analysis of 135 
patients with gastric adenocarcinoma who were ≥ 75 
years of age and underwent gastrectomy at our institu-
tion between January 2001 and December 2011. The 
clinicopathologic findings were determined according 
to the Japanese Classification of Gastric Carcinoma.15 
All patients underwent either distal partial, proximal 
partial, or total gastrectomy with regional dissection of 
the lymph nodes. Patients were periodically checked 
for early recurrence by diagnostic imaging (chest X-ray, 
upper gastrointestinal fiberscopy, ultrasonography, and 
computed tomography). Cause of death and patterns of 
recurrence were determined by reviewing their medical 
records, including laboratory data, ultrasonography, 
computed tomography, scintigrams, peritoneal punc-
tures, and laparotomies, or by direct inquiry with family 
members. We collected data of serum concentration of 
albumin from blood tests performed preoperatively and 
1 month postoperatively. This study was approved by 
our institutional review board (17A075), and informed 
consent requirement was waived for this retrospective 
study.
Statistical analysis
Differences between the two groups were evaluated us-
ing the Mann–Whitney U test. Receiver operating char-
acteristic (ROC) curves were constructed for patients’ 
survival status; area under the curve (AUC) values were 
compared to assess the discrimination ability of pre- 
and post-Alb levels. Survival curves were calculated 
Table 1. Correlation between clinicopathologic factors and serum albumin levels
Pre-Alb (g/dL)c P value Post-Alb (g/dL)d P value
Gender 0.32 0.024
Male (n = 93) 3.87 ± 0.53 3.51 ± 0.57
Female (n = 42) 3.8 ± 0.48 3.72 ± 0.53
Histology a 0.22 0.5
Differentiated (n = 83) 3.8 ± 0.53 3.63 ± 0.56
Undifferentiated (n = 52) 3.93 ± 0.47 3.49 ± 0.55z
Depth of invasion b 0.0032 0.044
T1 (n = 67) 3.97 ± 0.48 3.65 ± 0.59
T2 / 3 / 4 (n = 68) 3.73 ± 0.51 3.50 ± 0.52
Lymph node metastasis 0.051 0.36
Absence (n = 88) 3.91 ± 0.5 3.61 ± 0.53
Presence (n = 47) 3.74 ± 0.51 3.51 ± 0.62
Peritoneal metastasis 0.23 0.33
Absence (n = 126) 3.87 ± 0.5 3.59 ± 0.56
Presence (n  = 9) 3.62 ± 0.63 3.39 ± 0.58
Stage of disease 0.006 0.072
I / II (n = 99) 3.92 ± 0.49 3.63 ± 0.54
III / IV (n = 36) 3.66 ± 0.53 3.41 ± 0.59
Lymphatic invasion 0.7 0.5
Absence (n = 41) 3.88 ± 0.51 3.6 ± 0.6
Presence (n = 94) 3.84 ± 0.51 3.57 ± 0.55
Venous invasion 0.5 0.067
Absence (n = 46) 3.89 ± 0.51 3.66 ± 0.6
Presence (n = 89) 3.83 ± 0.51 3.53 ± 0.54
Child-Pugh classification < 0.0001 0.0082
A (n = 121) 3.95 ± 0.41 3.62 ± 0.54
B (n = 14) 3.02 ± 0.55 3.16 ± 0.64
All albumin measurements are expressed as mean ± standard deviation.
a Differentiated (papillary or tubular adenocarcinoma) or undifferentiated (poorly differentiated or mucinous adenocarcinoma, or sig-
net-ring cell carcinoma).
b T1, Tumor invasion of the lamina propria or submucosa; T2, tumor invasion of the muscularis propria; T3, tumor invaded the subsero-
sa; T4, tumor invasion is contiguous with or extends beyond the serosa or the tumor invades adjacent structures.
c Pre-Alb, preoperative serum albumin level
d Post-Alb, postoperative serum albumin level
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according to the Kaplan–Meier method. Differences be-
tween survival curves were examined with the log rank 
test. We used multivariate analysis of factors considered 
prognostic of either overall survival (OS) or disease-spe-
cific survival (DSS), with Cox’s proportional hazards 
model and a stepwise procedure. Covariates included in 
this analysis were age, sex, tumor size, histology, depth 
of invasion, lymph node metastasis, lymphatic vessel in-
vasion, blood vessel invasion, presence of distant metasta-
sis, pre-Alb level, post-Alb level, Child–Pugh classifica-
tion, and ASA score. The accepted level of significance 
was P < 0.05. GraphPad Prism (GraphPad Software, La 
Jolla, CA) and Stat View (Abacus Concepts, Berkeley, 
CA) software were used for the statistical analyses.
RESULTS
The mean pre- and post-Alb levels were 3.9 ± 0.51 g/dL 
and 3.6 ± 0.56 g/dL, respectively. Compared with the 
pre-Alb levels, post-Alb levels were lower in 83 patients 
and equivalent or greater in 52 patients. Table 1 shows 
the correlation between the various clinicopathologic 
factors and serum Alb levels. The pre-Alb levels of the 
patients with advanced GC patients and those with stage 
III/IV cancers were significantly lower than those of the 
patients with early GC patients (P = 0.0032) and those 
with stage I/II cancers (P = 0.006), respectively. In ad-
dition, the pre-Alb levels of patients with Child–Pugh 
grade B disease were significantly lower than those of 
patients with grade A disease (P < 0.0001). Post-Alb lev-
els of male patients and those with advanced GC were 
significantly lower than those of female patients (P = 
0.024) and those with early GC (P = 0.044), respectively. 
Furthermore, post-Alb levels of patients with Child–
Pugh grade B disease were significantly lower than 
those of patients with grade A disease (P = 0.0082).
 Among the 153 patients, 28 patients died of recur-
rent GC, and 23 patients died of other diseases. There 
was no statistical difference between the pre-Alb levels 
of the patients who died of recurrent GC, and those who 
were either still living or who had died of other diseases 
(Fig. 1a). However, post-Alb levels of patients who died 
of other diseases were significantly lower than levels of 
patients who were still alive (P = 0.0004; Fig. 1b). Fur-
thermore, post-Alb levels of patients who died of recur-
rent GC tended to be lower than levels of patients who 
were still alive (P = 0.068; Fig. 1b).
 ROC curves were then constructed for patient sur-
vival status, and AUC values were compared to assess 
the discrimination ability of pre- and post-Alb levels. 
For both OS and DSS, the AUC value of the post-Alb 
level was higher than that of the pre-Alb level, indicating 
that the post-Alb level was more predictive of OS and 
DSS than the pre-Alb level (Fig. 2). 
 For both pre-Alb and post-Alb levels, patients were 
then divided into two groups: those with Alb level ≥ 4 g/
dL (AlbHigh), and Alb level < 4 g/dL (AlbLow). Five-year 
OS rates did not significantly differ between the pre-Al-
bHigh group (53.9%) and the pre-AlbLow group (49.4%; P 
= 0.27; Fig. 3a); nor did the 5-year DSS rates (pre-Al-
bHigh: 78.9%, pre-AlbLow: 67.2%; P = 0.23; Fig. 3b). 
However, 5-year OS rates significantly differed between 
the post-AlbHigh group (78.6%) and post-AlbLow group 
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Fig. 1. Comparison of preoperative serum albumin levels (a) and postoperative serum albumin levels (b) to the cause of patient death.
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Fig. 2. Comparison of areas under the receiver operating curves (AUC) for outcome prediction. (a) Preoperative serum albumin level for 
overall survival (OS), (b) postoperative serum albumin level for OS (c) preoperative serum albumin level for disease-specific survival (DSS), 
and (d) postoperative serum albumin level for DSS.
Fig. 3. Comparison of overall survival (a) and disease-specific survival (b) according to preoperative serum albumin levels. Pre-AlbHigh, 
serum albumin level ≥ 4 g/ dL; Pre-AlbLow, serum albumin level < 4 g/dL.
(45.0%; P = 0.0051; Fig. 4a); as did the 5-year DSS rates 
(post-AlbLow: 67.5%; post-AlbHigh: 89.6%; P = 0.045; Fig. 
4b).
 Finally, multivariate analysis indicated that in addi-
tion to lymph node metastasis, distant metastasis, histol-
ogy, venous invasion, and ASA score, the post-Alb level 
was also an independent prognostic indicator for OS 
(Table 2), but not for DSS (Table 3).
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Fig. 4. Comparison of overall survival (a) and disease-specific survival (b) according to postoperative serum albumin levels. Post-AlbHigh, 
serum albumin level ≥ 4 g/ dL; Post-AlbLow, serum albumin level < 4 g/dL.
Table 2. Association of various factors with overall 
survival determined by the Cox proportional hazards 
model and a stepwise procedure
HR f 95% CI g P value
Histology (Differentiated vs. 
undifferentiated) a 0.508 0.286–0.903 0.021
Lymph node metastasis (n0–3) b 1.812 1.385–2.370 < 0.0001
Distant metastasis (Absent vs. 
present) 6.387 2.702–15.096 < 0.0001
Venous invasion (v0–3) c 1.61 1.119–2.316 0.01
Postoperative serum albumin 
level d 0.508 0.346–0.953 0.0318
ASA score e 1.832 1.107–3.031 0.0185
a Differentiated (papillary or tubular adenocarcinoma) or undif-
ferentiated (poorly differentiated or mucinous adenocarcinoma, or 
signet-ring cell carcinoma).
b Lymph node metastasis: N0, no regional lymph node metastasis; 
N1, metastasis in 1–2 regional lymph nodes; N2, metastasis in 3–6 
regional lymph nodes; N3, metastasis in 7 or more regional lymph 
nodes
c Venous invasion: v0–v3, grade of lymphatic invasion
d Continuous variable
e American Society of Anesthesiologists (ASA) score: I, normal 
healthy patient; II, patient with mild systemic disease; III, patient 
with severe systemic disease; IV, patient with severe systemic 
disease that is a constant threat to life; V, moribund patient who is 
not expected to survive without surgery; VI, patient who has been 
declared brain-dead. 
f HR, hazard ratio
g CI, confidence interval
Table 3. Association of various factors with disease 
specific survival determined by the Cox proportional 
hazards model and a stepwise procedure
HR d 95% CI e P value
Histology (Differentiated vs. 
undifferentiated) a 0.419 0.188–0.933 0.0332
Lymph node metastasis 
(n0–3) b 2.438 1.662–3.577 < 0.0001
Distant metastasis (Absent 
vs. present) 7.875 2.965–20.921 < 0.0001
Venous invasion (v0–3) c 3.041 1.696–5.453 0.0002
a Differentiated (papillary or tubular adenocarcinoma) or undif-
ferentiated (poorly differentiated or mucinous adenocarcinoma, or 
signet-ring cell carcinoma).
b Lymph node metastasis: N0, no regional lymph node metastasis; 
N1, metastasis in 1–2 regional lymph nodes; N2, metastasis in 3–6 
regional lymph nodes; N3, metastasis in 7 or more regional lymph 
nodes
c Venous invasion: v0–v3, grade of lymphatic invasion
d HR, hazard ratio
e CI, confidence interval
DISCUSSION
Because older patients with GC often have severe co-
morbidities, they may be high-risk surgical candidates; 
nevertheless, several studies have shown that the risk 
can be minimized by intensive care.16, 17 Advances in 
surgical techniques, and in anesthetic and postoperative 
intensive care, have increased the likelihood of these pa-
tients safely undergoing surgery. 
 However, GC often leads to malnutrition, owing 
to obstruction and bleeding from the tumor. Because 
malnutrition increases the rate of postoperative com-
plications, accurately evaluation of the preoperative nu-
tritional status of all GC patients is important. Various 
methods have been developed for evaluating patients’ 
nutritional status, including the prognostic nutritional 
index (PNI) and controlling nutrition status (CONUT) 
score. These measurements are reported to be closely 
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associated with the prognosis of cancer patients, which 
indicates that nutritional status has a critical bearing on 
cancer outcomes.3–9 Visceral proteins, such as albumin, 
prealbumin, and transferrin, are also examined in clini-
cal practice. Because those protein levels can be quickly 
and easily determined, they are frequently used to eval-
uate patients’ nutritional status. Pre-Alb levels have been 
shown to correlate with the clinical outcomes of medical 
and surgical patients.18–20 Because of its convenience, 
the current study used serum albumin level to assess 
the nutritional status and determined the correlation be-
tween serum albumin levels and prognosis in older GC 
patients. Our findings showed that the post-Alb level, 
but not pre-Alb level, was significantly correlated with 
OS and DSS. Furthermore, post-Alb level was an inde-
pendent prognostic factor in OS, but not for DSS. With 
regard to the correlation between serum albumin levels 
and cause of death, post-Alb level was significantly low-
er in patients who died of other diseases compared with 
those who were still alive. These results clearly indicate 
that post-Alb level is an indicator for risk of death by 
other diseases for older patients. Previously, Migita et al. 
used the PNI to evaluate patients’ preoperative immu-
nonutritional status and found that a low PNI score was 
associated with a higher risk of non-cancer death in GC 
patients.21 A similar study has shown that for older pa-
tients with gastric cancer, low PNI scores increases their 
chances of respiratory failure owing to pneumonia com-
pared with patients with high PNI scores.22 Taken to-
gether, these findings suggest that low nutritional status 
in older patients increases their risk of death from other 
diseases after surgery. Our results showed the impor-
tance of postoperative nutrition in terms of prognosis in 
older patients with GC, whereas preoperative nutritional 
status did not affect their outcomes. Post-Alb levels were 
low in 83 patients and equal or higher in 52 patients 
compared with the same patients’ pre-Alb levels. These 
results indicate that 60% of the older patients had gas-
trectomy-induced malnutrition. Unlike other procedures, 
gastrectomy can cause patients to become malnourished 
after their surgeries because of poor food intake as a re-
sult of decreased stomach volume. Therefore, prolonged 
malnutrition after gastrectomy, which can be evaluated 
by post-Alb level, may make patients susceptible to 
death from other diseases.
 Older populations are usually associated with high 
comorbidity rates. Comorbidities are likely to worsen 
both short-term and long-term outcomes. Therefore, 
we included ASA score as a covariate in multivariate 
analysis, which showed ASA score was an independent 
prognosis indicator for OS. 
 Liver dysfunction might affect the serum albumin 
level because albumin is produced in the liver. In this 
regard, both pre- and post Alb levels in patients with 
Child–Pugh grade B disease were significantly low-
er than those in patients with grade A disease, which 
implies that serum albumin levels are associated with 
liver function in addition to nutritional status. However, 
Child-Pugh classification was not an independent prog-
nostic indicator in our multivariate analysis, which indi-
cates that post-Alb levels are associated with the progno-
sis of older GC patients, independently of liver function 
or comorbidity.
 Preoperative nutritional support is known to be 
effective for moderate-to-severe malnutrition,23, 24 and 
postoperative complications are significantly decreased 
by nutritional support after gastrointestinal surgery.25 
In contrast, our results clearly demonstrated that low 
post-Alb levels were significantly associated with poor 
prognosis. Therefore, postoperative nutritional support 
might be effective in improving the prognosis of older 
gastric cancer patients. Recently, body weight loss was 
shown to be  the most important risk factor with regard 
to the patient compliance with adjuvant S-1 chemothera-
py in patients who underwent D2 gastrectomy for GC.26 
Therefore, postoperative nutritional support may im-
prove patient compliance with adjuvant S-1 chemothera-
py, which may further improve their prognosis.
 The present study has a few limitations. First, some 
bias was present because the study was retrospective. 
Second, we measured the serum albumin levels 1 month 
after surgery and used it as the postoperative parameter; 
however, the best time to measure the post-Alb level 
remains unclear. Third, the number of patients included 
in the current study was small; therefore, a large-scale, 
prospective randomized controlled trial is needed to 
confirm the results.
 In conclusion, the post-Alb level is useful for pre-
dicting the prognosis of older gastric cancer patients. 
Postoperative nutritional support might be effective in 
improving the prognosis of older gastric cancer patients.
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